Oric Pharmaceuticals Inc (ORIC)

04:32 AM

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

04:32 AM

04:30 AM

ORIC Strengthens Team with Strategic Equity Grants to Key New Hires - Stock Titan

04:30 AM

Apr 03, 2025

NEOS Investment Management LLC Purchases Shares of 45,476 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat

Apr 03, 2025

Apr 01, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Brokerages - MarketBeat

Apr 01, 2025

Mar 31, 2025

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 31, 2025

Mar 31, 2025

Oncology Pioneer ORIC Sets Stage for 2 Major Healthcare Conference Appearances - Stock Titan

Mar 31, 2025

Mar 31, 2025

Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World

Mar 31, 2025

Mar 31, 2025

Swiss National Bank Has $504,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 31, 2025

Mar 28, 2025

Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 28, 2025

Mar 26, 2025

ORIC stock touches 52-week low at $6.31 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

ORIC stock touches 52-week low at $6.31 amid market challenges - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

PNC Financial Services Group Inc. Buys 2,520 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 26, 2025

Mar 25, 2025

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times

Mar 25, 2025

Mar 25, 2025

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical - GlobeNewswire

Mar 25, 2025

Mar 25, 2025

Breakthrough: Novel Prostate Cancer Drug Demonstrates Powerful Two-Pronged Attack Strategy - Stock Titan

Mar 25, 2025

Mar 25, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9%Time to Sell? - MarketBeat

Mar 25, 2025

Mar 24, 2025

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance

Mar 24, 2025

Mar 24, 2025

Wedbush Reaffirms Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat

Mar 24, 2025

Mar 23, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% – Here’s What Happened - Defense World

Mar 23, 2025

Mar 22, 2025

(ORIC) Investment Report - news.stocktradersdaily.com

Mar 22, 2025

Mar 21, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 21, 2025

Mar 14, 2025

Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks

Mar 14, 2025

Mar 12, 2025

(ORIC) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Mar 12, 2025

Mar 07, 2025

ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan

Mar 07, 2025

Mar 07, 2025

Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

Mar 07, 2025

Mar 06, 2025

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Mar 06, 2025

Mar 06, 2025

ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat

Mar 06, 2025

Mar 06, 2025

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World

Mar 06, 2025

Mar 05, 2025

ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks

Mar 05, 2025

Mar 04, 2025

Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat

Mar 04, 2025

Mar 03, 2025

ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World

Mar 03, 2025

Mar 02, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade - MarketBeat

Mar 02, 2025

Mar 01, 2025

(ORIC) Investment Analysis and Advice - news.stocktradersdaily.com

Mar 01, 2025

Mar 01, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 - Defense World

Mar 01, 2025

Mar 01, 2025

ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at Guggenheim - Defense World

Mar 01, 2025

Mar 01, 2025

Wedbush Equities Analysts Lift Earnings Estimates for ORIC - Defense World

Mar 01, 2025

Feb 28, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst Upgrade - Defense World

Feb 28, 2025

Feb 26, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co. - MarketBeat

Feb 26, 2025

Feb 26, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim - MarketBeat

Feb 26, 2025

Feb 25, 2025

Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114 - TipRanks

Feb 25, 2025

Feb 25, 2025

ORIC® Pharmaceuticals Announces Focused Registrational - GlobeNewswire

Feb 25, 2025

Feb 25, 2025

Can ORIC Pharmaceuticals' Extended Cash Runway Fuel Success in Cancer Drug Development? - StockTitan

Feb 25, 2025